Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT

J Nucl Med. 2005 Mar;46(3):429-35.

Abstract

Standard application of CT intravenous contrast agents in combined PET/CT may lead to high-density artifacts on CT and attenuation-corrected PET. To avoid associated diagnostic pitfalls, we designed and compared different intravenous contrast injection protocols for routine whole-body PET/CT.

Methods: Whole-body PET/CT included a topogram and a single spiral CT scan (2-row) with or without intravenous contrast, followed by an emission scan. The CT scan was used for attenuation correction of the emission data. Four groups of 10 whole-body PET/CT referrals each were investigated: (A) no intravenous contrast agent, (B) biphasic injection (90 and 50 mL at 3 and 1.5 mL/s, respectively) of intravenous contrast (300 mg/mL iodine) and CT in the craniocaudal direction with a 30-s delay, (C) triple-phase injection (90, 40, and 40 mL at 3, 2, and 1.5 mL/s, respectively) in the craniocaudal direction with a 50-s delay, and (D) dual-phase injection (80 and 60 mL at 3 and 1.5 mL/s, respectively) in the caudocranial direction with a 50-s delay. CT image quality was assessed on a scale from 1 to 3, and CT and attenuation-corrected PET images were reviewed separately for contrast-induced artifacts.

Results: Average CT image quality was poorest for protocol A (1.0) but improved to 2.8 when using intravenous contrast agents (protocols B-D). Only protocols B and C resulted in contrast-induced image artifacts that were limited to the thorax. The most homogeneous intravenous contrast enhancement without high-density image artifacts on either CT or PET after CT-based attenuation correction was achieved with protocol D.

Conclusion: Dual-phase intravenous contrast injection and CT in the caudocranial direction with a 50-s delay yields reproducible high image quality and is now used routinely for combined diagnostic PET/CT at our hospital.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Contrast Media / administration & dosage*
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Image Enhancement / methods*
  • Injections, Intravenous / methods
  • Male
  • Middle Aged
  • Neoplasms / diagnostic imaging*
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Subtraction Technique*
  • Tomography, X-Ray Computed / methods
  • Whole-Body Counting / methods

Substances

  • Contrast Media
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18